| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Departments of Surgery (E.v.d.H., H.A.B., H.J.B.), Internal Medicine III (W.W.d.H., S.W.J.L., A.H.v.d.M., F.B., E.P.K.), Pathology (R.R.d.K.), Biostatistics (T.S.), and Nuclear Medicine (E.P.K., D.J.K.), Erasmus University Hospital, 3000 CA Rotterdam, The Netherlands; and Department of Pathology, University Hospital of Lausanne (F.T.B.), Lausanne, Switzerland
Address all correspondence and requests for reprints to: Erwin van der Harst, M.D., Department of Surgery, Erasmus University Hospital, Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: evanderharst{at}hotmail.com
Selecting the appropriate approach for resection and follow-up of pheochromocytomas (PCCs) is highly dependent upon reliable localization and exclusion of multifocal, bilateral, or metastatic disease. Metaiodobenzylguanidine (MIBG) scintigraphy was developed for functional localization of catecholamine-secreting tissues. Somatostatin receptor imaging (SRI) has a high sensitivity for localizing head and neck paragangliomas, but studies of intraabdominal PCCs are rare. In this study we review our experience of [123I]MIBG and SRI, performed since 1983 and 1989, respectively, in the work-up of primary and recurrent PCCs. Scintigraphic results were correlated with catecholamine secretion, size and site, malignancy, associated tumor syndromes, and morphological features.
[123I]MIBG scans were performed in a total of 75 patients, in 70 cases before resection of primary PCCs and in 5 cases because of recurrent disease. Ninety-one PCCs were resected. The overall detection rates were 83.3% and 89.8% for PCCs larger than 1.0 cm. Multifocal disease was detected in 4 patients with [123I]MIBG. [123I]MIBG uptake correlated with greater size of PCC (r = 0.33; P = 0.008) and greater concentration of plasma epinephrine (r = 0.32; P = 0.006). [123I]MIBG-negative PCCs (n = 14) had significantly (P = 0.01) smaller diameters than [123I]MIBG-positive tumors. Furthermore, [123I]MIBG uptake was significantly higher in unilateral (P = 0.02), benign (P = 0.02), sporadic (P = 0.02), intraadrenal (P = 0.02), and capsular invasive (P = 0.03) PCCs than in bilateral, malignant, MEN2A/2B-related, extraadrenal, and noninvasive PCCs, respectively. The detection rate of SRI was only 25% (8 of 32) for primary benign PCCs. In 14 patients metastases occurred, which were effectively visualized with [123I]MIBG in 8 of 14 cases. SRI was able to detect metastases in 7 of 8 cases, including 3 [123I]MIBG-negative metastatic cases. In addition, [123I]MIBG and SRI detected 2 recurrences.
In conclusion, [123I]MIBG uptake is correlated with the size, epinephrine production, and site of PCCs. Its role in bilateral and MEN2A/2B-related PCCs seems limited. In cases of recurrent elevation of catecholamines, localization of metastases and/or recurrence should be attempted with [123I]MIBG scintigraphy. In suspicious metastatic PCCs, SRI might be considered to supplement [123I]MIBG scintigraphy.
This article has been cited by other articles:
![]() |
B Havekes, A A van der Klaauw, M M Weiss, J C Jansen, A G L van der Mey, A H J T Vriends, B A Bonsing, J A Romijn, and E P M Corssmit Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas Endocr. Relat. Cancer, June 1, 2009; 16(2): 527 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Imani, V. G. Agopian, M. S. Auerbach, M. A. Walter, F. Imani, M. R. Benz, R. A. Dumont, C. K. Lai, J. G. Czernin, and M. W. Yeh 18F-FDOPA PET and PET/CT Accurately Localize Pheochromocytomas J. Nucl. Med., April 1, 2009; 50(4): 513 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, F. Li, H. Zhuang, H. Jing, Y. Du, and Z. Zeng 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma J. Nucl. Med., March 1, 2009; 50(3): 397 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. L. Boland, M. A. Blake, P. F. Hahn, and W. W. Mayo-Smith Incidental Adrenal Lesions: Principles, Techniques, and Algorithms for Imaging Characterization Radiology, December 1, 2008; 249(3): 756 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, A. Ling, I. Lazurova, K. T. Adams, S. Perera, and K. Pacak Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma J. Nucl. Med., October 1, 2008; 49(10): 1613 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pasquali, V. Rossi, G. Conzo, G. Pannone, P. Bufo, A. De Bellis, A. Renzullo, G. Bellastella, A. Colao, G. Vallone, et al. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells J. Mol. Endocrinol., June 1, 2008; 40(6): 263 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Zelinka, H. J L M Timmers, A. Kozupa, C. C Chen, J. A Carrasquillo, J. C Reynolds, A. Ling, G. Eisenhofer, I. Lazurova, K. T Adams, et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations Endocr. Relat. Cancer, March 1, 2008; 15(1): 311 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J.L.M. Timmers, M. Hadi, J. A. Carrasquillo, C. C. Chen, L. Martiniova, M. Whatley, A. Ling, G. Eisenhofer, K. T. Adams, and K. Pacak The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma J. Nucl. Med., October 1, 2007; 48(10): 1599 - 1606. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ilias, A. Sahdev, R. H Reznek, A. B Grossman, and K. Pacak The optimal imaging of adrenal tumours: a comparison of different methods Endocr. Relat. Cancer, September 1, 2007; 14(3): 587 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Intenzo, S. Jabbour, H. C. Lin, J. L. Miller, S. M. Kim, D. M. Capuzzi, and E. P. Mitchell Scintigraphic Imaging of Body Neuroendocrine Tumors RadioGraphics, September 1, 2007; 27(5): 1355 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J.L.M. Timmers, A. Kozupa, C. C. Chen, J. A. Carrasquillo, A. Ling, G. Eisenhofer, K. T. Adams, D. Solis, J. W.M. Lenders, and K. Pacak Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma J. Clin. Oncol., June 1, 2007; 25(16): 2262 - 2269. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Korner, M. Stockli, B. Waser, and J. C. Reubi GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting J. Nucl. Med., May 1, 2007; 48(5): 736 - 743. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kaji, J. A Carrasquillo, W M. Linehan, C. C Chen, G. Eisenhofer, P. A Pinto, E. W Lai, and K. Pacak The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome Eur. J. Endocrinol., April 1, 2007; 156(4): 483 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. van Essen, E. P. Krenning, P. P. Kooij, W. H. Bakker, R. A. Feelders, W. W. de Herder, J. G. Wolbers, and D. J. Kwekkeboom Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma J. Nucl. Med., October 1, 2006; 47(10): 1599 - 1606. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ezziddin, T. Logvinski, C. Yong-Hing, H. Ahmadzadehfar, H.-P. Fischer, H. Palmedo, J. Bucerius, M. J. Reinhardt, and H.-J. Biersack Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., February 1, 2006; 47(2): 223 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. E. H. Lam, C. J. M. Lips, P. L. Jager, R. P. F. Dullaart, E. G. W. M. Lentjes, P. P. van Rijk, and J. M. H. de Klerk Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5888 - 5895. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Kohane, J. R. Ingelfinger, K. Nimkin, and C.-L. Wu Case 16-2005 - A Nine-Year-Old Girl with Headaches and Hypertension N. Engl. J. Med., May 26, 2005; 352(21): 2223 - 2231. [Full Text] [PDF] |
||||
![]() |
M. A. Blake, M. K. Kalra, M. M. Maher, D. V. Sahani, A. T. Sweeney, P. R. Mueller, P. F. Hahn, and G. W. Boland Pheochromocytoma: An Imaging Chameleon RadioGraphics, October 1, 2004; 24(suppl_1): S87 - S99. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al. Malignant pheochromocytoma: current status and initiatives for future progress Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Kann, B. Wirkus, T. Behr, K.-J. Klose, and S. Meyer Endosonographic Imaging of Benign and Malignant Pheochromocytomas J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1694 - 1697. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF] |
||||
![]() |
W. M. Manger In Search of Pheochromocytomas J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4080 - 4082. [Full Text] [PDF] |
||||
![]() |
I. Ilias, J. Yu, J. A. Carrasquillo, C. C. Chen, G. Eisenhofer, M. Whatley, B. McElroy, and K. Pacak Superiority of 6-[18F]-Fluorodopamine Positron Emission Tomography Versus [131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4083 - 4087. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. O'Carroll Localization of Messenger Ribonucleic Acids for Somatostatin Receptor Subtypes (sstr1-5) in the Rat Adrenal Gland J. Histochem. Cytochem., January 1, 2003; 51(1): 55 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Pacak, D. S. Goldstein, J. L. Doppman, B. L. Shulkin, R. Udelsman, and G. Eisenhofer A ""Pheo"" Lurks: Novel Approaches for Locating Occult Pheochromocytoma J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3641 - 3646. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Conlin and W. C. Faquin Case 13-2001- A 19-Year-Old Man with Bouts of Hypertension and Severe Headaches N. Engl. J. Med., April 26, 2001; 344(17): 1314 - 1320. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |